Monday, May 23, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

Monoclonal Antibody Cures Late-Stage Marburg Infection in Monkeys

by Global Biodefense Staff
April 6, 2017
Monoclonal Antibody Cures Late-Stage Marburg Infection in Monkeys

A study led by scientists at the University of Texas Medical Branch Galveston National Laboratory and Mapp Biopharmaceutical has found that an experimental treatment cured 100 percent of guinea pigs and rhesus monkeys in late stages of infection with lethal levels of Marburg and Ravn viruses, relatives of the Ebola virus.

Although the Marburg and Ravn viruses are less familiar than Ebola virus, both can resemble Ebola in symptoms and outcomes in people, and both lack preventive and therapeutic countermeasures.

The study involved giving the animals a therapeutic candidate, MR191-N, which is a monoclonal antibody derived from a person who survived Marburg disease. Monoclonal antibodies are immune system fighters designed to bind to a specific part of an invading virus or bacterium to treat disease.

The authors report that two doses of MR191-N were able to confer protection of up to 100 percent when treatment was started up to 5 days post infection. Prior studies of different experimental Marburg treatments involved daily dosing for 7 and 14 days, respectively, with treatment beginning closer to the time of infection.

The research included collaborators from Vanderbilt University Medical Center, the University of Natural Resources and Life Sciences in Austria, and The Scripps Research Institute.

The researchers are now working with NIAID’s preclinical services group to perform the additional safety testing necessary to advance the monoclonal antibody treatment to initial human clinical studies.

Public health workers learned during the 2014-15 Ebola outbreak in West Africa that lack of available treatment options kept diseased and at-risk people away from treatment centers, making disease tracking and outbreak containment more difficult. They fear the same situation would develop in a large-scale Marburg outbreak.

The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) provided project funding.

Continued development will be supported through a Task Order awarded in 2017 under the Assistant Secretary for Preparedness and Response (ASPR) Biomedical Advanced Research and Development Authority (BARDA) Centers for Innovation in Advanced Development and Manufacturing (CIADM) program.

Tags: AntiviralsEbolaMarburg

Related Posts

Pathogens

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Johns Hopkins: Chemical in Leafy Greens May Slow Growth of Coronaviruses
Pathogens

Johns Hopkins: Chemical in Leafy Greens May Slow Growth of Coronaviruses

April 11, 2022
New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs
Medical Countermeasures

New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs

April 10, 2022
We’ll See More ‘Hybrids’ Like Omicron XE as COVID Continues to Evolve
Pathogens

We’ll See More ‘Hybrids’ Like Omicron XE as COVID Continues to Evolve

April 10, 2022
Load More

Latest News

NIH to Further Invest in Point-of-Care Technologies Research Network

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC